Who Optimizes SG&A Costs Better? argenx SE or Geron Corporation

Optimizing SG&A Costs: A Tale of Two Companies

In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability and operational efficiency. Over the past decade, argenx SE and Geron Corporation have demonstrated contrasting strategies in handling these costs.

From 2014 to 2023, argenx SE's SG&A expenses skyrocketed by over 16,000%, reflecting its aggressive expansion and investment in growth. In contrast, Geron Corporation's expenses increased by approximately 312%, indicating a more conservative approach.

By 2023, argenx SE's SG&A expenses were nearly 10 times higher than those of Geron Corporation, highlighting its commitment to scaling operations. This divergence in strategy underscores the different paths these companies have taken in the biotech landscape. As investors and industry watchers analyze these trends, the question remains: which approach will yield better long-term results?